Clinical trial
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704
Study timeline
Study start (actual)2019-10-09Date precision: day
Registry last updated2025-03-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small Cell Lung Cancerunresolved
Non-small Cell Lung Cancer, Squamousunresolved
Non-small Cell Lung Cancer, Non-squamousunresolved
Head and Neck Squamous Cell Carcinomaunresolved
Esophageal Squamous Cell Carcinomaunresolved
Gastric Adenocarcinomaunresolved
Gastroesophageal Junction Adenocarcinomaunresolved
Prostate Cancerunresolved
Melanomaunresolved
Interventions
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Seagen Inc.lead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
New YorkNew York, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1BaltimoreMaryland, United States1NashvilleTennessee, United States1PortlandOregon, United States1JacksonvilleFlorida, United States1OrlandoFlorida, United States1Ann ArborMichigan, United States1Las VegasNevada, United States1MadisonWisconsin, United States1GreenvilleSouth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04032704 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.